List of Excipients in Branded Drug EMVERM

Generic Drugs Containing EMVERM

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals LLC	mebendazole	64896-669	ANHYDROUS LACTOSE
Amneal Pharmaceuticals LLC	mebendazole	64896-669	CELLULOSE, MICROCRYSTALLINE
Amneal Pharmaceuticals LLC	mebendazole	64896-669	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in EMVERM?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
1	CELLULOSE, MICROCRYSTALLINE
1	FD&C YELLOW NO. 6

EMVERM Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

EMVERM is a 100 mg mebendazole chewable tablet marketed for intestinal helminth infections. Its excipient system supports tablet robustness, rapid disintegration, chewability, flavor acceptance, and dose administration in pediatric patients. The main commercial opportunities are improved taste masking, dye-free and lactose-free reformulation, pediatric-friendly liquid or orally disintegrating dosage forms, and geographic expansion in markets where mebendazole remains a first-line anthelmintic.

What is EMVERM and how is it positioned commercially?

EMVERM contains mebendazole, a benzimidazole anthelmintic. The FDA approved EMVERM under NDA 205926 in October 2016 as a 100 mg chewable tablet.[1] The labeled indications include treatment of enterobiasis caused by pinworm, ascariasis caused by roundworm, trichuriasis caused by whipworm, and hookworm infections.[1]

Attribute	EMVERM
Active ingredient	Mebendazole
Strength	100 mg
Dosage form	Chewable tablet
FDA application	NDA 205926
Initial FDA approval	October 2016
Primary users	Pediatric and adult patients
Administration	One 100 mg tablet, with dosing varying by infection
Therapeutic class	Anthelmintic
Biosimilar exposure	None; EMVERM is a small-molecule drug
Principal commercial differentiator	Branded chewable presentation and palatability

Mebendazole has been used for decades, limiting the value of conventional active-ingredient exclusivity. EMVERM’s commercial positioning instead depends on dosage form, taste, availability, packaging, supply reliability, and prescriber familiarity.

The FDA-approved product is especially relevant in pediatric treatment because chewable tablets reduce the need for swallowing an intact tablet or measuring a liquid suspension. That advantage is meaningful in mass-treatment programs, primary care, pediatrics, and settings where dosing simplicity affects adherence.

What excipients are used in EMVERM?

The EMVERM label identifies a multi-component excipient system designed to produce a flavored, chewable tablet.[1,2]

Excipient or component	Likely formulation function
Colloidal silicon dioxide	Glidant and powder-flow aid
Croscarmellose sodium	Disintegrant
FD&C Yellow No. 6	Colorant
Lactose monohydrate	Diluent and bulking agent
Magnesium stearate	Lubricant
Microcrystalline cellulose	Binder, diluent, and tablet-structure aid
Polacrilin potassium	Disintegrant and ion-exchange excipient
Povidone	Binder
Sodium lauryl sulfate	Wetting agent and processing aid
Sodium saccharin	High-intensity sweetener
Starch	Diluent, binder, or disintegration aid
Talc	Glidant and anti-adherent
Tutti-frutti flavor	Taste and sensory masking

The system combines insoluble structural excipients, superdisintegrants, a lubricant, sweetener, flavor, surfactant, and colorant. That combination is consistent with a compressed chewable tablet requiring sufficient hardness for packaging while retaining acceptable mouthfeel.

How does EMVERM’s excipient strategy affect product performance?

Taste masking

Mebendazole has limited aqueous solubility and can produce an unpleasant sensory profile. EMVERM uses tutti-frutti flavor and sodium saccharin to improve palatability. The flavor system is commercially important because treatment often involves children, and refusal or incomplete chewing can reduce effective dosing.

Taste masking depends on more than the flavor itself. Particle size, drug distribution, tablet porosity, saliva contact time, surfactant concentration, and the order in which sweetness and bitterness are perceived can affect acceptance. Sodium lauryl sulfate may improve wetting and dispersion but can also influence oral sensory perception at higher concentrations.

A competing product could pursue a stronger opportunity through:

• More effective bitterness suppression
• Reduced aftertaste
• Fruit or neutral flavor options
• Lower tablet chalkiness
• Improved friability and mouthfeel
• A smaller tablet at the same 100 mg dose

Chewability and disintegration

Croscarmellose sodium and polacrilin potassium provide disintegration support. Microcrystalline cellulose and starch help establish tablet structure. The formulation must balance rapid breakup with sufficient mechanical strength during bottling, shipment, and dispensing.

A product that disintegrates too slowly may be difficult for children to chew. A product that is too soft may chip, powder, or lose dose uniformity. The commercial target is a tablet that survives distribution but breaks down rapidly with chewing and saliva.

Manufacturing robustness

The excipient system supports conventional dry blending and compression. Magnesium stearate reduces sticking and improves ejection, while colloidal silicon dioxide and talc can improve flow and reduce tooling problems.

Manufacturing risks include:

• Lubricant overmixing, which can reduce tablet hardness and slow disintegration
• Flavor volatility during processing and storage
• Segregation of low-dose flavor or color components
• Moisture sensitivity of the compressed tablet
• Variability in chewable-tablet hardness
• Changes in sensory performance after long-term storage

These risks create opportunities for a manufacturer with stronger process controls, direct-compression expertise, or a more stable flavor-delivery system.

What formulation patents protect EMVERM?

EMVERM’s commercial protection is more likely to depend on regulatory status, trademarks, formulation know-how, and market execution than on new chemical-entity exclusivity. Mebendazole is an established small molecule, and the FDA approval was not based on a new active ingredient.

The FDA’s approved labeling does not itself establish a broad, enforceable patent monopoly over all mebendazole chewable tablets. Patent scope must be evaluated through current USPTO records, the FDA Orange Book, prosecution histories, and litigation databases.

The most commercially relevant potential claim categories would be:

1. Specific chewable-tablet compositions.
2. Flavor or taste-masking systems.
3. Particle-size distributions and drug-excipient ratios.
4. Manufacturing processes that improve content uniformity or tablet strength.
5. Packaging systems that protect flavor, potency, or stability.
6. Pediatric methods of administration.

A formulation patent would have limited blocking value if a competitor could design around the claimed excipients, substitute a different flavor system, use a liquid suspension, or commercialize a non-chewable dosage form.

When does EMVERM lose exclusivity?

EMVERM did not receive new chemical entity exclusivity because mebendazole was previously approved. The FDA granted a period of three-year exclusivity for the new drug application if the approval was based on new clinical investigations essential to approval. That period would have expired in 2019, assuming the standard three-year period applied from the October 2016 approval date.[1,3]

Exclusivity or protection	EMVERM status
New chemical entity exclusivity	Not applicable
Three-year approval exclusivity	Approximately 2016-2019
Orphan-drug exclusivity	Not identified for the approved indications
Pediatric exclusivity	No extension identified in the cited FDA materials
Biosimilar exclusivity	Not applicable
Patent-based exclusivity	Requires current Orange Book and USPTO verification
Trademark protection	Separate from FDA exclusivity and potentially continuing

Regulatory exclusivity and patent protection are separate. Expiration of three-year exclusivity does not automatically establish immediate generic launch if enforceable patents remain. Conversely, the absence of a blocking patent does not guarantee immediate competition because a generic sponsor still needs an approved ANDA and commercial supply.

What is the Orange Book status of EMVERM?

EMVERM is associated with NDA 205926. The Orange Book is the controlling FDA source for listed patents, exclusivity codes, therapeutic-equivalence evaluations, and approved products.[3]

The principal Orange Book questions for diligence are:

• Whether EMVERM has active patent listings.
• Whether any listed patents cover the chewable formulation rather than mebendazole generally.
• Whether a generic product has an A-rated therapeutic-equivalence code.
• Whether any patent certifications have been filed against listed claims.
• Whether the reference product has current marketing status.

An Orange Book listing would be most relevant for ANDA applicants considering Paragraph IV certification. A Paragraph IV challenge could trigger patent litigation under the Hatch-Waxman framework and potentially create a 180-day first-applicant commercial opportunity if the statutory conditions are met.[4]

Which companies are challenging EMVERM?

A verified Paragraph IV challenge, settlement agreement, or active Hatch-Waxman litigation should be confirmed through FDA ANDA records, Orange Book updates, PACER, and public company filings. The cited FDA label and DailyMed record do not establish a current litigation or settlement position.[1,2]

The competitive threat is broader than a formal Paragraph IV filing. Potential competitors include:

• Generic manufacturers of mebendazole chewable tablets
• International suppliers of mebendazole tablets
• Manufacturers of oral suspensions
• Public-health suppliers offering lower-cost albendazole
• Compounding pharmacies serving pediatric patients
• Developers of fixed-dose antiparasitic combinations

Because mebendazole is an established drug, a generic sponsor may have relatively limited clinical-development requirements compared with a novel therapy. The main development burden is pharmaceutical equivalence, bioequivalence where applicable, manufacturing validation, stability, and product quality.

What formulation opportunities exist for EMVERM competitors?

Dye-free and lactose-free chewable tablets

EMVERM contains FD&C Yellow No. 6 and lactose monohydrate.[1,2] A dye-free or lactose-free product could target patients with excipient sensitivities, caregiver preferences, institutional formularies, or procurement specifications.

Removing lactose may require replacing both bulking and compression functions. Potential alternatives include mannitol, sorbitol, isomalt, cellulose derivatives, or starch-based systems. Each substitute changes hardness, friability, hygroscopicity, sweetness, cooling effect, and mouthfeel.

Oral suspension

A ready-to-use suspension could address children unable to chew tablets. The commercial tradeoff is increased packaging complexity, sedimentation control, preservative selection, dosing-device requirements, and microbial stability.

A powder-for-reconstitution product may reduce shipping weight and improve shelf stability, but it shifts preparation requirements to caregivers or health workers.

Orally disintegrating tablet

An orally disintegrating tablet could provide administration without chewing. The formulation would require rapid disintegration, low friability, acceptable taste, and adequate dose loading. Mebendazole’s low solubility and relatively high 100 mg dose make tablet mass and sensory masking important development constraints.

Unit-dose and public-health packaging

Blister packs, calendar packs, and unit-dose sachets could improve dispensing accuracy and reduce medication loss. Packaging designed for heat and humidity could support tropical markets and mass drug-administration programs.

How strong is the EMVERM patent estate?

EMVERM’s patent strength should be assessed as formulation-dependent rather than molecule-dependent. The active ingredient does not provide meaningful new-molecule exclusivity. The defensibility of the branded product therefore depends on:

Factor	Strategic assessment
Active ingredient	Weak protection because mebendazole is established
Chewable dosage form	Potentially protectable but design-around risk is high
Flavor system	Usually narrow and vulnerable to substitution
Excipient combination	Potential claim value depends on unexpected performance data
Manufacturing process	Stronger if it produces measurable quality advantages
Trademark and brand	Can support pricing after generic entry
Regulatory file	Provides reference-product status but not perpetual exclusivity
Supply chain	Can create practical barriers without creating patent rights

A formulation patent is stronger when it claims a narrow composition tied to a demonstrated technical result, such as superior taste scores, improved stability, lower friability, or faster disintegration. Claims that merely list common excipients in conventional ranges are more vulnerable to obviousness and design-around arguments.

What commercial opportunities does EMVERM create?

The most attractive opportunities are differentiated products that solve administration or procurement problems rather than simply copy the branded tablet.

Premium pediatric formulation

A superior-tasting, dye-free, lactose-free chewable tablet could support a premium position in pediatric outpatient care. The product would need reliable sensory data and a clear labeling advantage.

Low-cost generic supply

A low-cost generic can compete on formulary placement, wholesaler access, and public-sector tenders. Manufacturing scale and stable supply may matter more than minor excipient differences.

Geographic expansion

Mebendazole is used in many international markets for soil-transmitted helminth infections. WHO identifies albendazole and mebendazole as key medicines for preventive chemotherapy programs.[5] Opportunities exist in regions with high helminth burden, but pricing is constrained in public-health procurement.

Combination products

Mebendazole could be evaluated in combination with agents addressing broader parasitic coverage, although clinical, regulatory, and patent analysis would be required. Combination products may improve convenience but introduce new safety, interaction, and development requirements.

Contract manufacturing and licensing

A branded owner or generic sponsor could license:

• A pediatric taste-masking platform
• A stable oral suspension
• A heat-resistant packaging system
• A chewable-tablet manufacturing process
• Regional distribution rights
• Public-health procurement access

The strongest licensing asset is likely to be a differentiated dosage form with validated stability and sensory performance, not the mebendazole molecule itself.

What revenue exposure does EMVERM create?

Public FDA materials identify the approved product and regulatory history but do not report EMVERM revenue. Revenue exposure is therefore driven by market share, net price, payer coverage, generic entry, and public-sector demand rather than by a long remaining NCE exclusivity period.

Key commercial risks include:

• Rapid price erosion after generic approval
• Substitution by albendazole
• Limited treatment duration and low prescription frequency
• Tender-driven pricing in endemic markets
• Pediatric adherence failures caused by taste or tablet texture
• Supply disruption from specialized chewable-tablet manufacturing
• Reimbursement restrictions for antiparasitic medicines

Brand value can persist after generic entry if the manufacturer maintains pediatric preference, reliable distribution, and strong institutional contracts. That value is unlikely to support a large premium without a meaningful formulation or service advantage.

Key Takeaways

• EMVERM is a 100 mg mebendazole chewable tablet approved by the FDA in 2016.
• Its excipient system combines disintegrants, binders, lubricants, sweetener, surfactant, colorant, lactose, and fruit flavor.
• The central product advantage is pediatric administration, not active-ingredient novelty.
• Three-year FDA exclusivity would have ended around 2019; mebendazole has no new chemical entity exclusivity.
• The most credible product opportunities are dye-free, lactose-free, better-tasting chewables, oral suspensions, orally disintegrating tablets, and heat-stable unit-dose packaging.
• Patent strength is likely to depend on narrow formulation and process claims supported by performance data.
• EMVERM has no biosimilar risk because it is a small-molecule drug.
• Generic and public-health competition can pressure price even without a formal Paragraph IV challenge.
• The most defensible licensing assets are validated pediatric formulation technologies and reliable regional supply channels.

FAQs

Is EMVERM a biologic or a small-molecule drug?

EMVERM is a small-molecule drug containing mebendazole. Biosimilar approval pathways do not apply. Competition would generally arise through generic-drug pathways such as an ANDA.

Does EMVERM contain lactose?

Yes. Lactose monohydrate is listed among the inactive ingredients in the FDA labeling.[1,2]

Is EMVERM dye-free?

No. The labeled formulation contains FD&C Yellow No. 6.[1,2] A dye-free version could provide a straightforward formulation differentiation opportunity.

Can a competitor launch a mebendazole liquid instead of a chewable tablet?

Yes, a liquid suspension would be a different dosage-form strategy. It would require appropriate FDA approval and would face separate stability, dosing, microbiological, and formulation requirements.

What is the main barrier to a generic EMVERM product?

The main barriers are pharmaceutical development, product quality, regulatory approval, manufacturing scale, and commercial distribution. Any active Orange Book patent listing or unresolved Hatch-Waxman litigation would add a legal barrier.

References

1. U.S. Food and Drug Administration. (2016). EMVERM (mebendazole) chewable tablets prescribing information. NDA 205926.

2. National Library of Medicine. (n.d.). DailyMed: EMVERM- mebendazole tablet, chewable. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications. FDA.

5. World Health Organization. (2023). Helminth control in school-age children: A guide for managers of control programmes. WHO.